Beneficient Secures $8.75 Million Primary Capital Commitment from Quartus AI Fund, Strengthening Collateral and Liquidity

BENF
April 10, 2026

Beneficient closed a primary capital commitment of $8.75 million with Quartus AI Fund LP, a growth‑stage AI and technology venture fund managed by Quartus Capital Partners LLC. The transaction was structured through resettable convertible preferred stock that can be converted at the holder’s election into Beneficient’s Class A common stock. In exchange, Beneficient recorded an unrealized gain of approximately $1.2 million, reflecting the appreciation of the Fund’s existing portfolio.

The deal increased the collateral backing Beneficient’s ExAlt loan portfolio by $9.77 million and added an equivalent amount of tangible book value to the company’s balance sheet. Prior to the transaction, Beneficient’s tangible book value attributable to public shareholders was zero as of December 31 2025; the pro‑forma adjustment now raises it to $9.77 million, a move that directly addresses the company’s liquidity challenges and improves its current ratio, which was reported at 0.27.

Beneficient’s GP Primary Commitment Program is designed to provide primary capital solutions to qualified private investment funds. By partnering with Quartus AI Fund, which has a strong track record in vertical AI investing, Beneficient aligns its capital strategy with a high‑performing fund that can help support the company’s loan portfolio and future growth initiatives.

Interim CEO James Silk said, "We are pleased to partner with Quartus AI Fund LP and welcome Quartus Capital Partners LLC to our GP Primary Commitment Program." He added, "We believe Quartus is an exceptional firm at the forefront of vertical AI investing, and this transaction reflects our continued commitment to closing transactions that drive shareholder value and enhance the value of the collateral backing our ExAlt loan portfolio."

The capital infusion strengthens Beneficient’s liquidity position and enhances the collateral backing its loan portfolio, but the company’s overall financial health remains weak, with a current ratio of 0.27. The transaction is a key step in Beneficient’s broader strategy to secure capital from specialized investors and address ongoing liquidity challenges.

The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.